Veracyte flagged Decipher Prostate test data supporting hormone-therapy addition to radiation

Veracyte says a retrospective Phase III NRG/RTOG 0815 analysis found its Decipher Prostate test identified intermediate-risk patients likely to benefit from adding short-term hormone therapy to radiation; low-risk profiles showed little added benefit. Data will be presented at ASTRO on Sept. 29, 2026.